



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/030,332	02/15/2002	Yuji Ishihara	2599 USOP	5909

7590 02/03/2003

Mark Chao
Takeda Pharmaceuticals North America Inc
Suite 500
475 Half Day Road
Lincolnshire, IL 60069

EXAMINER

CHANG, CELIA C

ART UNIT	PAPER NUMBER
1625	9

DATE MAILED: 02/03/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 10/030,332	Applicant(s) Ishihara et al.
Examiner Celia Chang	Art Unit 1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Jul 29, 2002

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-39 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1-39 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

4) Interview Summary (PTO-413) Paper No(s). _____

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____

6) Other: _____

Art Unit: 1625

DETAILED ACTION

1. This application is a 371 of PCT/JP00/02765. Restriction is required under 35 U.S.C. 121 and 372. This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Group I, claim 14, drawn to piperidinylpyrrolidinyl compounds. If this group is elected, generic claims 1-13, 15-21, 26-28, 30-39 reading on the subject matter wherein R1 and R2 forms a piperidinyl ring can be prosecuted together with the elected compounds to the extend of the elected compounds.

Group II, claims 3-13, 30-39 in part (nonpiperidinyl), drawn to compounds with two heterocyclic rings. If this group is elected, a further election of a single disclosed species reading on R1-R2 forms heterocyclic ring which is not piperidine is also required. Claims 1-2, 15-21, 26-28 reading on the subject matter wherein R1 and R2 forms a heterocyclic nonpiperidine ring can be prosecuted together with the elected compounds to the extend of the elected compounds.

Group III, claims 1-2, remaining compounds, drawn to heterocyclic amine/carbamide. If this group is elected, a further election of a single disclosed species reading on R1 and R2 are independent substituent is also required. Claims 15-21, 26-28 reading on the subject matter wherein R1 and R2 do not form a ring can be prosecuted together with the elected compounds to the extend of the elected compounds.

Group IV, claims 22-24, drawn to composition containing multiple active ingredients. If this group is elected, a further election of a single disclosed composition is also required. Further restriction may be required.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: in accordance with PCT Administrative Instruction, Annex B, section(f) "Markush Practice" (B)(2)(v) *When dealing with alternatives, if it can be*

Art Unit: 1625

shown that at least one Markush alternative is not novel over the prior art, the question of unity of invention shall be reconsidered by the examiner. In the instant case, it was found that at least one Markush alternative i.e. when R1 and R2 are independent substituents, is not novel, see CA 78:43180, RN 39629-97-5, 39629-98-6, 39630-09-6, 39630-10-9 anticipated group II compounds.

In accordance with 37 CFR 1.499, applicant is required in reply to this action to elect a single invention to which the claims must be restricted.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang whose telephone number is 703-308-4702. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Alan Rotman, can be reached on (703) 308-4698. The fax phone number for the organization where this application or proceeding is assigned is 703-308-7922 with courtesy message to the examiner at 703-308-4702.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

WP/Chang
Jan 28, 2003


Celia Chang
Primary Examiner
Art Unit 1625